Adc Therapeutics SA (ADCT)

Name: Adc Therapeutics SA (ADCT) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Adc Therapeutics SA (ADCT)

Stock Card

$1.15

$0.03 (2.23%)

As on 28-Aug-2026 13:40EDT

Market cap

$123 Mln

Revenue (TTM)

$79 Mln

P/E Ratio

P/B Ratio

3.4

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Adc Therapeutics SA (ADCT) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 1.07 High: 1.15

52 Week Range

Low: 0.78 High: 4.98

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-7.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-1.4
Debt to Equity

0
Book Value

$--
EPS

$-0.7
Face value

--
Shares outstanding

127,667,695

7 Years Aggregate

CFO

$-975.48 Mln

EBITDA

$-1,047.46 Mln

Net Profit

$-1,201.61 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Adc Therapeutics SA (ADCT)	-67.6	0.4	-66.6	-64.4	-3.9	-47.8	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021
Adc Therapeutics SA (ADCT)	77.4	-56.8	-81.0	-36.9
S&P Small-Cap 600	4.0	13.9	-17.4	25.3
BSE Sensex	9.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Adc Therapeutics SA (ADCT)	1.1	122.6	78.8	-96.9	-53.3	--	--	3.4
AC Immune SA - ADR	2.7	288.3	17.5	-43.2	-172.4	-107.8	--	6.1
Crispr Therapeutics AG (CRSP)	57.7	5,753.2	13.4	-451.1	-3,529.8	-24.6	--	3.2

Shareholding Pattern

View Details

About Adc Therapeutics SA (ADCT)

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug... Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. Read more

CEO & Director

Dr. Ameet Mallik M.B.A., M.S.
CEO & Director

Dr. Ameet Mallik M.B.A., M.S.
Headquarters

Epalinges
Website

https://www.adctherapeutics.com

FAQs for Adc Therapeutics SA (ADCT)

What is the current share price of Adc Therapeutics SA (ADCT) Today?

The share price of Adc Therapeutics SA (ADCT) is $1.15 (NYSE) as of 28-Aug-2026 13:40 EDT. Adc Therapeutics SA (ADCT) has given a return of -3.9% in the last 3 years.

What is the current PB & PE ratio of Adc Therapeutics SA (ADCT)?

Since, TTM earnings of Adc Therapeutics SA (ADCT) is negative, P/E ratio is not available.
The P/B ratio of Adc Therapeutics SA (ADCT) is 3.42 times as on 21-Aug-2026, a 33 premium to its peers’ median range of 2.58 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-3.72	-2.86
2024	-1.33	-1.04
2023	-0.57	-0.92
2023	-0.31	-0.50
2022	-1.97	3.90

What is the 52 Week High and Low of Adc Therapeutics SA (ADCT)?

The 52-week high and low of Adc Therapeutics SA (ADCT) are Rs 4.98 and Rs 0.78 as of 30-Aug-2026.

What is the market cap of Adc Therapeutics SA (ADCT)?

Adc Therapeutics SA (ADCT) has a market capitalisation of $ 123 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Adc Therapeutics SA (ADCT)?

Before investing in Adc Therapeutics SA (ADCT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.